[
  {
    "uuid": "915ea7af791c0a4d9574a8e320d769a1bee12f53",
    "url": "https://www.app.com.pk/domestic/dengue-cases-decline-as-temperature-drops-in-punjab/",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "Zakaullah",
    "published": "2023-12-30T07:42:00Z",
    "title": "Dengue cases decline as temperature drops in Punjab",
    "text": "LAHORE, Dec 30 (APP): In a positive turn, the recent drop in temperatures in Punjab has coincided with a decrease in dengue virus cases across the province.\nHowever, concerns linger as Lahore continues to bear the brunt of the outbreak, reporting 7,027 confirmed cases. The latest data from the Health Department discloses a total of 15,182 dengue cases spread across 36 districts in Punjab this year. Despite the overall decline, Lahore, witnessing an additional 6 cases, remains a hotspot. Sialkot and Chakwal reported one case each in the last 24 hours.\nCurrently, 25 dengue patients are receiving treatment in various Punjab hospitals, with 8 of them located in Lahore district hospitals. Punjab Health Secretary Ali Jaan Khan issued a compelling plea, urging citizens to maintain clean and dry surroundings as a preventive measure. He stressed the importance of cooperation with health department teams actively working to curb the Dengue outbreak.\nFor those seeking dengue treatment, information, or wishing to register complaints, a free helpline (1033) is available through the health department. The secretary emphasized the need for vigilance and proactive measures to contain the alarming spread of dengue in Punjab.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "positive",
    "categories": [
      "Weather",
      "Health"
    ],
    "external_links": [],
    "external_images": [],
    "entities": {
      "persons": [
        {
          "name": "ali jaan khan",
          "sentiment": "none"
        }
      ],
      "organizations": [
        {
          "name": "health department",
          "sentiment": "none"
        },
        {
          "name": "punjab health",
          "sentiment": "none"
        }
      ],
      "locations": [
        {
          "name": "punjab lahore",
          "sentiment": "none"
        },
        {
          "name": "punjab",
          "sentiment": "none"
        },
        {
          "name": "chakwal",
          "sentiment": "none"
        },
        {
          "name": "sialkot",
          "sentiment": "none"
        },
        {
          "name": "lahore",
          "sentiment": "none"
        }
      ]
    },
    "rating": null,
    "crawled": "2023-12-30T15:00:02.271+02:00",
    "updated": "2023-12-30T15:00:02.271+02:00"
  },
  {
    "uuid": "e14e2623c745084fb70d1a8c138754e80e06f1a6",
    "url": "https://www.perfil.com/noticias/cordoba/escandalo-en-la-fpa-hablo-un-exagente-y-admitio-practicas-irregulares-en-operativos-antidrogas.phtml",
    "ord_in_thread": 0,
    "author": "Andy Ferreyra",
    "published": "2025-04-09T21:23:00Z",
    "title": "Escándalo en la FPA: habló un exagente y admitió prácticas irregulares en operativos antidrogas",
    "text": "Un exagente de la Fuerza Policial Antinarcotráfico (FPA) de Córdoba, bajo el seudónimo de \"Germán\", expuso los métodos ilegales utilizados por efectivos para financiar investigaciones en el interior provincial. Según su testimonio, agentes utilizaban droga incautada y dinero propio para pagar a dateros, en un esquema que operaba al margen de la fiscalía y que actualmente tiene imputado a un fiscal por encubrimiento.\nGermán detalló que, en zonas como Cruz del Eje, la complejidad para investigar redes narco llevaba a los agentes a retener parte de la droga decomisada en allanamientos -sin registrarla- o a juntar dinero entre los agentes para compensar a informantes. \"Por ejemplo, si secuestraban 50 gramos, reportaban 30 y los otros 20 volvían al círculo para usarlos en otra investigación\", admitió.\nCrecen las causas judiciales por la penetración narco en los sectores sociales más vulnerables\nEl objetivo: agilizar casos en pueblos donde “se conoce todo el mundo” y la presencia de “un auto desconocido puede alertar a los investigados”, haciendo que se caiga la investigación, relató el entrevistado en el programa Última Pregunta por Radio Continental Córdoba.\nAunque insistió en que no todos los efectivos participaban, reconoció que la práctica era \"una bomba de tiempo\" tolerada por los resultados estadísticos. \"La fiscalía no lo hubiera permitido, pero en Cruz del Eje servía\", afirmó.\nFiscal imputado y fallas sistémicas\nLas revelaciones coinciden con la imputación del fiscal Raúl Ramírez, acusado de no investigar la desaparición de 353 gramos de cocaína y 158 gramos de marihuana que debían ser enviados al depósito judicial. Según la causa, Ramírez, su secretario Patricio Bazán y el jefe de la FPA local, Mauricio Oyola, habrían ocultado el faltante, permitiendo que la droga se usara en operativos ilegales.\nElevan a juicio al fiscal Raúl Ramírez por no investigar la desaparición de droga secuestrada por la FPA\nLa investigación -iniciada tras una denuncia del exjefe de la FPA, Adrián Salcedo- también expuso deficiencias en la custodia de pruebas: sobres con droga permanecían años sin ser enviados, y las actas de traslado se manipulaban sin controles.\nEl caso ya suma 12 imputados, incluidos 10 policías y dos civiles, por asociación ilícita y encubrimiento. Germán, el exagente FPA, aseguró que, pese a los riesgos legales, la presión por resultados incentivaba estas prácticas: \"Si una circunscripción no allanaba en meses, exigían acción\".\nMientras Ramírez espera su elevación a juicio (requiere previa destitución por sus fueros), el escándalo pone en jaque los protocolos de una fuerza de élite y revela la tensión entre la eficacia y la legalidad en la lucha contra el narcotráfico.\nFoto en texto: ilustrativa.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "spanish",
    "sentiment": "negative",
    "categories": [
      "Crime, Law and Justice",
      "Politics",
      "Social Issue"
    ],
    "topics": [
      "Crime, Law and Justice->investigation (criminal)",
      "Crime, Law and Justice->corruption",
      "Crime, Law and Justice->drug related crimes",
      "Politics->civil rights",
      "Politics->government",
      "Politics->safety of citizens",
      "Social Issue->discrimination",
      "Social Issue->abusive behaviour",
      "Social Issue->social problem"
    ],
    "ai_allow": true,
    "has_canonical": false,
    "breaking": true,
    "webz_reporter": false,
    "external_links": [],
    "entities": {
      "persons": [
        {
          "name": "Germán",
          "sentiment": "negative"
        }
      ],
      "locations": [],
      "organizations": [
        {
          "name": "FPA",
          "sentiment": "negative",
          "tickers": []
        },
        {
          "name": "Fuerza Policial Antinarcotráfico",
          "sentiment": "negative",
          "tickers": []
        }
      ]
    },
    "syndication": {
      "syndicated": null,
      "syndicate_id": null,
      "first_syndicated": false
    },
    "trust": {
      "categories": [],
      "bias": null,
      "source": {
        "type": null,
        "city": null,
        "state": null,
        "country": null,
        "domain_type": null,
        "agency": null,
        "organization_name": null
      }
    },
    "rating": null,
    "crawled": "2025-04-10T00:56:53.658+03:00",
    "updated": "2025-04-10T00:56:53.658+03:00"
  },
  {
    "uuid": "3a0624ff42b44fd4a3ed3f7080ebf7c1f32e074f",
    "url": "https://www.stocktitan.net/news/MLYS/mineralys-therapeutics-announces-publication-of-pivotal-phase-2-qcbfrfrp93pv.html",
    "ord_in_thread": 0,
    "author": "StockTitan",
    "published": "2025-04-23T21:23:00Z",
    "title": "Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM) | MLYS Stock News",
    "text": "Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)\nMineralys Therapeutics (NASDAQ: MLYS) announced the publication of its pivotal Phase 2 Advance-HTN trial results in the New England Journal of Medicine (NEJM). The study evaluated lorundrostat in patients with uncontrolled or resistant hypertension.\nKey findings showed that lorundrostat 50 mg achieved a 15.4 mmHg absolute reduction and a 7.9 mmHg placebo-adjusted reduction (p=0.001) in 24-hour ambulatory blood pressure at week 12. The drug demonstrated consistent efficacy across different patient groups, including those on varying baseline medications, gender, and racial demographics.\nThe treatment showed a favorable safety profile with modest changes in potassium, sodium, and eGFR. The results were previously presented at ACC.25 in Chicago. The company plans to present additional data from their pivotal Phase 3 Launch-HTN trial at an upcoming medical conference.\nMineralys Therapeutics (NASDAQ: MLYS) ha annunciato la pubblicazione dei risultati del suo studio cruciale di Fase 2 Advance-HTN sul New England Journal of Medicine (NEJM). Lo studio ha valutato lorundrostat in pazienti con ipertensione non controllata o resistente.\nI risultati principali hanno mostrato che lorundrostat 50 mg ha ottenuto una riduzione assoluta della pressione arteriosa ambulatoriale nelle 24 ore di 15,4 mmHg e una riduzione aggiustata per placebo di 7,9 mmHg (p=0,001) alla settimana 12. Il farmaco ha dimostrato un’efficacia costante in diversi gruppi di pazienti, inclusi quelli con terapie di base differenti, genere e gruppi etnici.\nIl trattamento ha evidenziato un profilo di sicurezza favorevole con variazioni contenute di potassio, sodio e eGFR. I risultati erano già stati presentati all’ACC.25 di Chicago. L’azienda prevede di presentare ulteriori dati del loro studio cruciale di Fase 3 Launch-HTN in una prossima conferenza medica.\nMineralys Therapeutics (NASDAQ: MLYS) anunció la publicación de los resultados de su ensayo pivotal de Fase 2 Advance-HTN en el New England Journal of Medicine (NEJM). El estudio evaluó lorundrostat en pacientes con hipertensión no controlada o resistente.\nLos hallazgos clave mostraron que lorundrostat 50 mg logró una reducción absoluta de 15,4 mmHg y una reducción ajustada por placebo de 7,9 mmHg (p=0,001) en la presión arterial ambulatoria de 24 horas a la semana 12. El medicamento demostró eficacia constante en diferentes grupos de pacientes, incluyendo aquellos con distintos tratamientos base, género y grupos raciales.\nEl tratamiento mostró un perfil de seguridad favorable con cambios modestos en potasio, sodio y eGFR. Los resultados se presentaron previamente en ACC.25 en Chicago. La compañía planea presentar datos adicionales de su ensayo pivotal de Fase 3 Launch-HTN en una próxima conferencia médica.\nMineralys Therapeutics (NASDAQ: MLYS)는 그들의 중요한 2상 Advance-HTN 임상시험 결과를 New England Journal of Medicine (NEJM)에 발표했다고 밝혔습니다. 이 연구는 통제되지 않거나 저항성 고혈압 환자에서 로룬드로스타트를 평가했습니다.\n주요 결과는 로룬드로스타트 50mg이 12주차 24시간 활동성 혈압에서 15.4 mmHg의 절대 감소와 7.9 mmHg의 위약 보정 감소(p=0.001)를 달성했다는 점을 보여주었습니다. 이 약물은 다양한 기저 약물 복용 환자군, 성별 및 인종 그룹에서 일관된 효능을 나타냈습니다.\n치료는 칼륨, 나트륨, eGFR의 변화가 미미한 양호한 안전성 프로필을 보였습니다. 결과는 이전에 시카고에서 열린 ACC.25에서 발표되었습니다. 회사는 다가오는 의학 학회에서 3상 Launch-HTN 임상시험의 추가 데이터를 발표할 계획입니다.\nMineralys Therapeutics (NASDAQ : MLYS) a annoncé la publication des résultats de son essai pivot de phase 2 Advance-HTN dans le New England Journal of Medicine (NEJM). L’étude a évalué le lorundrostat chez des patients souffrant d’hypertension non contrôlée ou résistante.\nLes résultats clés ont montré que le lorundrostat 50 mg a permis une réduction absolue de 15,4 mmHg et une réduction ajustée par rapport au placebo de 7,9 mmHg (p=0,001) de la pression artérielle ambulatoire sur 24 heures à la semaine 12. Le médicament a démontré une efficacité constante dans différents groupes de patients, incluant ceux sous divers traitements de base, selon le sexe et les origines ethniques.\nLe traitement a présenté un profil de sécurité favorable avec des modifications modestes du potassium, du sodium et du DFG estimé. Les résultats avaient déjà été présentés lors de l’ACC.25 à Chicago. La société prévoit de présenter des données supplémentaires issues de leur essai pivot de phase 3 Launch-HTN lors d’une prochaine conférence médicale.\nMineralys Therapeutics (NASDAQ: MLYS) gab die Veröffentlichung der Ergebnisse seiner entscheidenden Phase-2-Studie Advance-HTN im New England Journal of Medicine (NEJM) bekannt. Die Studie untersuchte Lorundrostat bei Patienten mit unkontrolliertem oder resistentem Bluthochdruck.\nWesentliche Ergebnisse zeigten, dass Lorundrostat 50 mg eine absolute Reduktion des 24-Stunden-Ambulanzblutdrucks um 15,4 mmHg und eine placebokorrigierte Reduktion um 7,9 mmHg (p=0,001) in Woche 12 erreichte. Das Medikament zeigte eine konsistente Wirksamkeit in verschiedenen Patientengruppen, einschließlich unterschiedlicher Basismedikationen, Geschlecht und ethnischer Herkunft.\nDie Behandlung wies ein günstiges Sicherheitsprofil mit moderaten Veränderungen bei Kalium, Natrium und eGFR auf. Die Ergebnisse wurden zuvor auf der ACC.25 in Chicago vorgestellt. Das Unternehmen plant, weitere Daten aus der entscheidenden Phase-3-Studie Launch-HTN auf einer bevorstehenden medizinischen Konferenz zu präsentieren.\n- Strong efficacy data with significant blood pressure reduction of 15.4 mmHg absolute and 7.9 mmHg placebo-adjusted\n- Publication in prestigious New England Journal of Medicine validates clinical significance\n- Favorable safety and tolerability profile\n- Consistent efficacy across diverse patient populations\n- Novel mechanism of action addressing unmet medical need\n- Phase 3 Launch-HTN trial results still pending full disclosure\n- Additional long-term safety data still needed through Transform-HTN extension trial\nInsights\nLorundrostat shows clinically meaningful blood pressure reduction in resistant hypertension patients by targeting the previously unaddressed aldosterone pathway.\nThe publication of the Advance-HTN trial in the New England Journal of Medicine represents significant validation for lorundrostat's clinical potential. The data demonstrates a\nWhat's mechanistically important is lorundrostat's novel approach targeting aldosterone dysregulation. Current antihypertensive therapies do not directly decrease aldosterone production, despite its established role in blood pressure elevation. This represents the first potential therapeutic specifically addressing this pathway.\nThe trial results show consistent efficacy regardless of baseline medication count (two vs. three or more), gender, or race (white and black patients). This broad efficacy profile is particularly valuable since resistant hypertension patients typically have therapeutic options.\nThe safety profile shows only modest changes to potassium, sodium, and eGFR - important parameters to monitor with drugs affecting the renin-angiotensin-aldosterone system. The favorable tolerability in this trial population suggests potential for use in broader applications.\nThe 15.4 mmHg absolute reduction in blood pressure is particularly notable given these patients were already on optimized antihypertensive regimens. As noted in the article, even modest blood pressure reductions correlate with substantial decreases in major cardiovascular events, suggesting lorundrostat addresses a significant unmet medical need.\nNEJM publication validates Mineralys' hypertension drug with positive Phase 2/3 data in a large market with high unmet need.\nMineralys Therapeutics' publication in the New England Journal of Medicine represents significant external validation of their Phase 2 clinical program for lorundrostat. This milestone enhances scientific credibility and raises the company's profile among key opinion leaders in cardiology.\nThe clinical data shows lorundrostat achieved statistically significant blood pressure reductions (p=0.001) in patients with uncontrolled or resistant hypertension. The efficacy across diverse patient populations suggests potential for broad market applicability if approved.\nStrategically, lorundrostat appears well-positioned as a potential first-in-class aldosterone synthase inhibitor specifically targeting hypertension. The company has efficiently advanced its clinical program, completing both the pivotal Phase 2 Advance-HTN trial and Phase 3 Launch-HTN trial with positive results reported for both.\nThe ongoing Transform-HTN open-label extension will provide additional long-term safety data, which will strengthen the regulatory package. With two completed pivotal trials showing positive results, the company appears to be positioning for a potential regulatory submission.\nThe uncontrolled and resistant hypertension market represents a significant commercial opportunity with innovation in recent years. Lorundrostat addresses an established biological pathway (aldosterone dysregulation) that current therapies don't directly target, potentially carving out a distinct position in treatment algorithms.\nWith the NEJM publication and presentation at the American College of Cardiology's Annual Scientific Session, Mineralys is building important scientific awareness that could accelerate clinical adoption if lorundrostat reaches the market.\n– Significant blood pressure reductions among patients with uncontrolled or resistant hypertension treated with lorundrostat reinforce key role of dysregulated aldosterone in disease onset and progression –\n– Detailed results from the second pivotal Phase 3 Launch-HTN trial to be presented at an upcoming medical conference and published in a peer-reviewed publication –\nRADNOR, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that the New England Journal of Medicine (NEJM) published the detailed results from the Company’s pivotal Phase 2 Advance-HTN trial, the first of two pivotal trials evaluating lorundrostat in patients with uncontrolled hypertension (uHTN) or resistant hypertension (rHTN). The full manuscript is titled, “Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension,” and is featured in the April 23, 2025 issue of NEJM.\nThe key data from the publication showed that lorundrostat 50 mg demonstrated a 15.4 mmHg absolute reduction and a 7.9 mmHg placebo-adjusted reduction (p=0.001), in 24-hour ambulatory blood pressure at week 12. Lorundrostat worked equally well in those taking two baseline medications and those taking three or more, and in both men and women as well as in white and black patients. Lorundrostat demonstrated a favorable safety and tolerability profile, with modest changes in potassium, sodium and eGFR.\n“The publication of our Advance-HTN trial results in the New England Journal of Medicine is a significant milestone that underscores both the strength of our clinical data and the potentially transformative nature of this new class of medicines that could help address dysregulated aldosterone, an unaddressed, key driver of hypertension,” stated Jon Congleton, Chief Executive Officer of Mineralys Therapeutics. “Prior studies have shown that even modest reductions in systolic blood pressure can lead to a substantial decrease in the incidence of major cardiovascular events. The blood pressure reductions with lorundrostat observed in the Advance-HTN trial are particularly meaningful given the well-established correlation between elevated blood pressure, dysregulated aldosterone production and cardiovascular risk.”\n“The significant blood pressure lowering with lorundrostat 50 mg in the Advance-HTN trial was seen in patients treated by specialists who were taking an optimized standardized antihypertensive regimen – those patients with true uncontrolled or resistant hypertension that desperately need new options to lower their blood pressure,” stated Luke Laffin, M.D., co-director of the Center for Blood Pressure Disorders in the Heart, Vascular & Thoracic Institute at Cleveland Clinic and the study’s lead author. “Currently available therapies to treat hypertension do not decrease aldosterone production in the body, and we know aldosterone dysregulation is a driving factor in the blood pressure elevation of many of our patients. The findings reinforce the critical role of aldosterone in the pathogenesis of hypertension and the potential of lorundrostat to address unmet medical needs facing patients with uncontrolled or treatment-resistant disease.”\nThe NEJM publication of the detailed Advance-HTN results follows a late-breaking presentation of the data at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25) in Chicago on March 29, 2025, and the announcement of positive topline results from both Advance-HTN and Launch-HTN earlier in March.\nMineralys plans to provide additional data from the pivotal Phase 3 Launch-HTN at an upcoming medical conference and in a peer-reviewed publication. Additionally, the ongoing Transform-HTN open-label extension trial allows subjects to continue to receive lorundrostat and obtain additional safety and efficacy data.\nAbout Hypertension\nHaving sustained, elevated blood pressure (or hypertension) increases the risk of heart disease, heart attack and stroke, which are leading causes of death in the U.S. In 2020, more than 670,000 deaths in the U.S. included hypertension as a primary or contributing cause. Hypertension and related health issues resulted in an average annual economic burden of about\nLess than\nAbout Lorundrostat\nLorundrostat is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uHTN or rHTN, as well as CKD and OSA. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, an observed half-life of 10-12 hours and demonstrated approximately a\nIn a Phase 2, proof-of-concept trial (Target-HTN) in uncontrolled or resistant hypertensive subjects, once-daily lorundrostat demonstrated statistically significant and clinically meaningful blood pressure reduction in both automated office blood pressure measurement and 24-hour ambulatory blood pressure monitoring. Adverse events observed were a modest increase in serum potassium, decrease in estimated glomerular filtration rate, urinary tract infection and hypertension with one serious adverse event possibly related to study drug being hyponatremia.\nAbout Advance-HTN\nThe Advance-HTN trial (NCT05769608) was a randomized, double-blind, placebo-controlled Phase 2 clinical trial that evaluated the efficacy and safety of lorundrostat for the treatment of uHTN or rHTN, when used as an add-on therapy to a standardized background treatment of two or three antihypertensive medications in adult subjects. Subjects who met screening criteria had their existing hypertension medications discontinued and started on a standard regimen of an angiotensin II receptor blocker (ARB) and a diuretic, if previously on two medications, or a standard regimen of ARB, diuretic and calcium channel blocker if previously on three to five medications. Subjects who remained hypertensive despite the standardized regimen were then randomized into three cohorts and treated for twelve weeks: lorundrostat 50 mg once-daily (QD), lorundrostat 50 mg QD and an option to titrate to 100 mg QD at week four based on defined criteria, or placebo. The trial’s primary endpoint was the change in 24-hour ambulatory systolic blood pressure at week twelve from baseline for active cohorts versus placebo.\nAbout Mineralys\nMineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.\nForward Looking Statements\nMineralys Therapeutics cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to, statements regarding: the potential therapeutic benefits of lorundrostat; the Company’s expectation that Advance-HTN and Launch-HTN may serve as pivotal trials in any submission of a new drug application (NDA) to the United States Food and Drug Administration (FDA); the Company’s ability to evaluate lorundrostat as a potential treatment for CKD, OSA, uHTN or rHTN; and the planned future clinical development of lorundrostat and the timing thereof. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: topline results that we report are based on a preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data related to the clinical trial and such topline data may not accurately reflect the complete results of a clinical trial; our future performance is dependent entirely on the success of lorundrostat; potential delays in the commencement, enrollment and completion of clinical trials and nonclinical studies; later developments with the FDA may be inconsistent with the feedback from the completed end of Phase 2 meeting, including whether the proposed pivotal program will support registration of lorundrostat which is a review issue with the FDA upon submission of an NDA; the results of our clinical trials, including the Advance-HTN and Launch-HTN trials, may not be deemed sufficient by the FDA to serve as the basis for an NDA submission or regulatory approval of lorundrostat; our dependence on third parties in connection with manufacturing, research and clinical and nonclinical testing; unexpected adverse side effects or inadequate efficacy of lorundrostat that may limit its development, regulatory approval and/or commercialization; unfavorable results from clinical trials and nonclinical studies; results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results; regulatory developments in the United States and foreign countries; our reliance on our exclusive license with Mitsubishi Tanabe Pharma to provide us with intellectual property rights to develop and commercialize lorundrostat; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.\nContact:\nInvestor Relationsinvestorrelations@mineralystx.com\nMedia Relations\nTom Weible\nElixir Health Public Relations\nPhone: (1) 515-707-9678\nEmail: tweible@elixirhealthpr.com",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "positive",
    "categories": [
      "Health"
    ],
    "topics": [
      "Health->medical test",
      "Health->health treatment and procedure",
      "Health->medical profession"
    ],
    "ai_allow": true,
    "has_canonical": false,
    "breaking": false,
    "webz_reporter": false,
    "external_links": [
      "https://www.globenewswire.com/Tracker?data=MDR3GVOhuh7LKWni55uuT-cJvEYwE6A8TDexhFPnoCVmUsfT1yjx8D0xf62ojs2Ox5kqSko2tVeu_ZN9zjkDeXp-3VkQYH4fDhpNOF9DbRyPGHvY7qbnvO4xJ_WYGdFf",
      "https://www.globenewswire.com/Tracker?data=vZhjh_rTqK06CGD7n7tv7Kb3S7MjUgmw6MGQsRTANeiT8rny3L1mFTUFCr6nrTRIiJt-PBn3XF-MCqNSylACAYV7B2f1aZ4PqkGrmYIjxuWB3hi4SAb4XKV5Dw4WtzLKbkH8hMg7CgUvDwN28L0_InqOREeX6Uz2EjR2w2rsJOk=",
      "https://www.globenewswire.com/Tracker?data=RuK9x3ZIkeye4U0ywaSSibAY0V3zMJiHBiT49mLpzU81KZc0uPTW_-3Yfvun7rCAN_kHcWjL7jSpvGHjH8oB-zjvHX_-FcgIUL4uFFyqWBGZuSamLJyHKhUNOBCA0RoXwTZ5RfQPETYPgxyHuc_2Ig==",
      "https://www.globenewswire.com/Tracker?data=RW1fyuwhcrNvu6s0gBXad5kJ917HY4CHqC92N71X64koxqtYC0bgdnPcgL3R7xAw58n4XQOY2f_q1pB0KO7sxAccuYFik3oHpM8jL3ZItYkYToBrV5phr0rVnjnEkZc4UfLigImCyMz0h53iVfAP01t9j6FQ6RLwHhpAzdXTA20runPoM791Rua7UcJztNU3GKlRgqB9kId2eJMdRLNnXkdQj1EFuilyqV8AY-W7h54=",
      "https://www.globenewswire.com/Tracker?data=7j8cfAo-NUdnYEYl8vAliS8zL5RyCOxgkEK3zCHqmHrXzIGwdk4b8a1JsooRMc9Z_wG7PY1LWYyVYODHQeYbMcgwyuXQif2koc9SASDJMQg=",
      "https://www.globenewswire.com/Tracker?data=VvELYqyWvlJY8UcX-Ob-8izuZ0uAMjROh-7um44Xl3oSy9MLh1cLDOry0VABXoq2Gp-rgiz_xKiR0T4JEgv_H3vvPDQCz7niCTWOUD59iPqJQfGYSBAPYRw4TOPzWInaTIXkCawt5PaNXRJ6PowMupXluqoF2lpq3QFrg-hoIve-89cSzX60DqRRFiCe_XDCDyTTw65vUQMfFrEnx5dMUQ==",
      "https://www.globenewswire.com/Tracker?data=OmZLZu3vKfyJIrjalk7SMyFS3GlryvPKWvOkrWwH-1dW9vATJlO30Df4WnZjdFH-_DQA5Mb4IKRdr6jKr-X02hauOkjZQZwsDzVQCgrpkaG3weAryqMvKapDSTeeDNaUHAFi5u7AHsrFuR3-o5khIQ==",
      "https://www.globenewswire.com/Tracker?data=cOeS2Nq6Sc8MUTkdQMdj5-wvHC_s7EBaUpdHkt33FpTcFmaaicd1VBGvSIWzxjkf3ImyYR7E4S6wfdYANVQdvZk6qB4f8mQGgmom01JkJZuTLw8GvvZhDUScZKR8vZ-g",
      "https://globenewswire.com/Tracker?data=RuK9x3ZIkeye4U0ywaSSibAY0V3zMJiHBiT49mLpzU81KZc0uPTW_-3Yfvun7rCAN_kHcWjL7jSpvGHjH8oB-zjvHX_-FcgIUL4uFFyqWBGZuSamLJyHKhUNOBCA0RoXwTZ5RfQPETYPgxyHuc_2Ig==",
      "https://globenewswire.com/Tracker?data=MDR3GVOhuh7LKWni55uuT-cJvEYwE6A8TDexhFPnoCVmUsfT1yjx8D0xf62ojs2Ox5kqSko2tVeu_ZN9zjkDeXp-3VkQYH4fDhpNOF9DbRyPGHvY7qbnvO4xJ_WYGdFf",
      "https://globenewswire.com/Tracker?data=VvELYqyWvlJY8UcX-Ob-8izuZ0uAMjROh-7um44Xl3oSy9MLh1cLDOry0VABXoq2Gp-rgiz_xKiR0T4JEgv_H3vvPDQCz7niCTWOUD59iPqJQfGYSBAPYRw4TOPzWInaTIXkCawt5PaNXRJ6PowMupXluqoF2lpq3QFrg-hoIve-89cSzX60DqRRFiCe_XDCDyTTw65vUQMfFrEnx5dMUQ==",
      "https://globenewswire.com/Tracker?data=7j8cfAo-NUdnYEYl8vAliS8zL5RyCOxgkEK3zCHqmHrXzIGwdk4b8a1JsooRMc9Z_wG7PY1LWYyVYODHQeYbMcgwyuXQif2koc9SASDJMQg=",
      "https://globenewswire.com/Tracker?data=OmZLZu3vKfyJIrjalk7SMyFS3GlryvPKWvOkrWwH-1dW9vATJlO30Df4WnZjdFH-_DQA5Mb4IKRdr6jKr-X02hauOkjZQZwsDzVQCgrpkaG3weAryqMvKapDSTeeDNaUHAFi5u7AHsrFuR3-o5khIQ==",
      "https://globenewswire.com/Tracker?data=cOeS2Nq6Sc8MUTkdQMdj5-wvHC_s7EBaUpdHkt33FpTcFmaaicd1VBGvSIWzxjkf3ImyYR7E4S6wfdYANVQdvZk6qB4f8mQGgmom01JkJZuTLw8GvvZhDUScZKR8vZ-g",
      "https://www.globenewswire.com/Tracker",
      "https://globenewswire.com/Tracker?data=RW1fyuwhcrNvu6s0gBXad5kJ917HY4CHqC92N71X64koxqtYC0bgdnPcgL3R7xAw58n4XQOY2f_q1pB0KO7sxAccuYFik3oHpM8jL3ZItYkYToBrV5phr0rVnjnEkZc4UfLigImCyMz0h53iVfAP01t9j6FQ6RLwHhpAzdXTA20runPoM791Rua7UcJztNU3GKlRgqB9kId2eJMdRLNnXkdQj1EFuilyqV8AY-W7h54=",
      "https://globenewswire.com/Tracker?data=vZhjh_rTqK06CGD7n7tv7Kb3S7MjUgmw6MGQsRTANeiT8rny3L1mFTUFCr6nrTRIiJt-PBn3XF-MCqNSylACAYV7B2f1aZ4PqkGrmYIjxuWB3hi4SAb4XKV5Dw4WtzLKbkH8hMg7CgUvDwN28L0_InqOREeX6Uz2EjR2w2rsJOk="
    ],
    "entities": {
      "persons": [],
      "locations": [],
      "organizations": []
    },
    "syndication": {
      "syndicated": false,
      "syndicate_id": null,
      "first_syndicated": false
    },
    "trust": {
      "categories": [],
      "bias": null,
      "source": {
        "type": null,
        "city": null,
        "state": null,
        "country": null,
        "domain_type": null,
        "agency": null,
        "organization_name": null
      }
    },
    "rating": null,
    "crawled": "2025-04-24T00:31:00.306+03:00",
    "updated": "2025-04-24T00:31:00.306+03:00"
  },
  {
    "uuid": "70b0008987897a48235f7069042c92fcac045d16",
    "url": "https://www.infobae.com/colombia/2023/12/30/sindicatos-celebraron-alza-de-salario-minimo-con-mensaje-contundente-a-empresarios/",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "Juan Sánchez Romero",
    "published": "2023-12-30T15:27:00Z",
    "title": "Sindicatos celebraron alza de salario mínimo con mensaje contundente a empresarios",
    "text": "Tras semanas de negociación e incertidumbre, en la noche del viernes 29 de diciembre se conoció que el salario mínimo en Colombia para el año 2024 tendrá un aumento del 12,07%, según anunció la ministra del Trabajo, Gloria Inés Ramírez, lo que significa que los trabajadores verán incrementados sus ingresos en 140.000 pesos, de manera que pasarán de tener un ingreso base de 1.160.000 pesos a un pago de 1.300.000 aproximadamente.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "spanish",
    "sentiment": "positive",
    "categories": [
      "Labor",
      "Economy, Business and Finance"
    ],
    "external_links": [
      "https://news.google.com/publications/CAAqBwgKMJGwngww0M2vAw?hl=es-419&gl=CO&ceid=CO%3Aes-419",
      "https://whatsapp.com/channel/0029Va4oNEALikgEL4Y8mb2K",
      "https://news.google.com/publications/CAAqBwgKMJGwngww0M2vAw",
      "https://www.news.google.com/publications/CAAqBwgKMJGwngww0M2vAw?hl=es-419&gl=CO&ceid=CO%3Aes-419",
      "https://www.whatsapp.com/channel/0029Va4oNEALikgEL4Y8mb2K"
    ],
    "external_images": [],
    "entities": {
      "persons": [],
      "organizations": [],
      "locations": []
    },
    "rating": null,
    "crawled": "2023-12-30T17:34:29.709+02:00",
    "updated": "2023-12-30T18:06:55.475+02:00"
  },
  {
    "uuid": "0e6a4c249700356779cb4f9ac8f14fe57da5ea6e",
    "url": "https://www.soychile.cl/Osorno/Politica/2024/04/18/856663/actor-alvaro-gomez-alcalde-osorno.html",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "SoyChile",
    "published": "2024-04-18T00:00:00Z",
    "title": "Actor Álvaro Gómez reúne las firmas requeridas y será candidato a alcalde de Osorno",
    "text": "Contento y agradecido se mostró el actor Álvaro Gómez, oriundo de la ciudad de Osorno, que hoy está enfocado en su campaña política para ser el próximo alcalde de esta comuna. Esto luego de sobrepasar los 615 patrocinios que exige el Servicio Electoral para que los candidatos independientes puedan estar en la papeleta de los comicios municipales de octubre de este año.“Agradezco a cada uno de los vecinos de Osorno que firmaron para que pueda ser candidato a alcalde de nuestra comuna y a todas las personas que se han sumado con sus ideas, anhelos y experiencia a este proyecto independiente que busca abrir las puertas del municipio a todos”, comentó.Gómez señaló que estas elecciones serán cruciales para el futuro de Osorno y dijo que “quienes han estado en la administración de La Municipalidad de Osorno durante los últimos 30 años, hoy están en deuda con la comunidad osornina. No se puede pretender seguir dirigiendo el destino de la ciudad con un municipio a puertas cerradas que no cuida ni escucha a su gente”.Por último, el ahora aspirante al sillón alcaldicio de Osorno indicó que su candidatura responde a la petición que le hicieron las organizaciones sociales de levantar un proyecto ciudadano que sea independiente de los partidos políticos y que ponga en el centro el bienestar de las personas.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "spanish",
    "sentiment": "positive",
    "categories": [
      "Politics",
      "Human Interest"
    ],
    "external_links": [],
    "external_images": [],
    "entities": {
      "persons": [],
      "organizations": [],
      "locations": []
    },
    "rating": null,
    "crawled": "2024-04-19T00:24:41.600+03:00",
    "updated": "2024-04-19T00:24:41.600+03:00"
  },
  {
    "uuid": "1f9bd7cea7a68aa3d148c02c3fa37402a115b212",
    "url": "https://www.cdt.ch/news/mondo/continuano-le-ricerche-dei-dispersi-a-valencia-mentre-il-maltempo-si-abbatte-sullandalusia-368494",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "Red. Online",
    "published": "2024-11-01T07:41:00Z",
    "title": "Continuano le ricerche dei dispersi a Valencia, mentre il maltempo si abbatte sull'Andalusia",
    "text": "Continuano le ricerche dei dispersi a Valencia, mentre il maltempo si abbatte sull'Andalusia Il bilancio delle vittime [nell'alluvione in Spagna](https://www.cdt.ch/news/mondo/una-famiglia-ticinese-a-valencia-siamo-bloccati-qui-fino-a-sabato-il-rientro-ci-costera-2500-franchi-368428) fa sempre più paura. È salito, infatti, a 158 il numero di morti confermati: 155 nell'area di Valencia, mentre altre tre persone sono morte in Castilla-La Mancha e in Andalusia. L'epicentro del dramma rimane attualmente l'hinterland di Valencia, una città sotto shock nonché parzialmente isolata. Se, infatti, l'aeroporto rimane funzionante, i treni resteranno invece fuori uso per almeno 15 giorni, mentre notevoli danni alla rete stradale limitano la circolazione delle auto.È in diverse aree della sua periferia dove si concentra il grosso dei morti: almeno 45 (di cui sei ospiti di una casa di riposo) a Paiporta, altre 13 tra La Torre e Castellar, mentre non è ancora certa la cifra, che si teme alta, dei deceduti a Sedaví. Le ricerche La ricerca dei dispersi, intanto, continua senza tregua, «casa per casa», ha detto il premier spagnolo Pedro Sánchez. «Il nostro impegno, per terra, mare e aria, con tutti i mezzi e per tutto il tempo necessario, è volto a ritrovare le persone scomparse». Quest'oggi, hanno fatto sapere i media spagnoli, 500 soldati dell'esercito si uniranno ai 1.200 messi in campo dall'Unità di Emergenza militare (UME), che da giorni ormai si impegnano nelle operazioni di ricerca, mentre il numero dei dispersi, al momento, rimane ignoto. Due ministri del governo spagnolo si uniranno, inoltre, al Centro di coordinamento operativo integrato che sta supervisionando la situazione insieme al governo regionale valenciano: il focus sarà riposto sul ripristino delle strade ancora bloccate. In un altro giorno destinato a veder lievitare il numero di morti, una buona notizia: il ministero degli Esteri dell''Ecuador ha reso noto che sette degli otto ecuadoriani dispersi in seguito alle inondazioni che hanno ucciso almeno 158 persone a Valencia e dintorni sono stati ritrovati vivi. L'ambasciata ecuadoriana a Madrid e i consolati di Valencia, Madrid e Barcellona stanno monitorando la situazione nel caso in cui vengano identificate altre persone, ha fatto sapere il ministero ai media spagnoli. Altre regioni L'allerta maltempo, nel frattempo, rimane alta. «L'episodio di piogge torrenziali e forti inondazioni che ha causato più di 155 morti a Valencia continuerà per tutto il fine settimana», ha avvertito Rubén del Campo, portavoce dell'Agenzia meteorologica di Stato (AEMET), nelle dichiarazioni rilasciate a El País ieri sera. E così è stato. L'AEMET mantiene in allerta cinque comunità oggi, venerdì, inizio di un lungo fine settimana festivo in cui la DGT ha chiesto ai cittadini di non recarsi nell'area di Valencia, Andalusia, Isole Baleari, Catalogna, Estremadura. Particolare preoccupazione, in queste ore, è stata registrata in Andalusia, dove l'allerta ha raggiunto il grado rosso nelle zone costiere di Huelva, Andévalo e Condado, almeno fino alle nove del mattino. Un forte temporale si è infatti abbattuto sull'area di Huelva alle due del mattino, allagando gran parte della città. Nei villaggi vicini alla capitale andalusa sono stati registrati fino a 100 litri per metro quadrato nelle prime ore del mattino. Secondo il servizio di emergenza della Junta de Andalucía, sono stati segnalati più di 40 episodi di inondazione anche ad Aljaraque, Cartaya, Punta Umbría e Gibraleón. Su X, il presidente della Giunta dell'Andalusia, Juanma Moreno, ha chiesto alla popolazione di Huelva di non uscire di casa se non strettamente necessario, invitando i cittadini alla «prudenza» e a «evitare spostamenti o qualsiasi rischio non necessario». Una DANA anomala Le intense precipitazioni che in questi giorni stanno colpendo la Spagna sono provocate da un fenomeno noto come DANA (Depresion Aislada en Niveles Altos, o depressione isolata ad alto livello): [ne avevamo parlato qui](https://www.cdt.ch/news/mondo/cose-la-dana-il-fenomeno-meteorologico-che-ha-colpito-la-spagna-368320). L'AEMET ha fatto sapere oggi che la DANA continuerà a causare condizioni meteorologiche avverse fino a domenica: una virulenza, insieme alla persistenza, del tutto nuove. Tanto che fra i meteorologi spagnoli, si legge sui media locali, c'è qualcuno che parla di «DANA anomala» o, addirittura, di «DANA di nuova generazione».",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "italian",
    "sentiment": "negative",
    "categories": [
      "Disaster and Accident",
      "Human Interest",
      "Weather"
    ],
    "ai_allow": true,
    "canonical": false,
    "webz_reporter": false,
    "external_links": [],
    "external_images": [],
    "entities": {
      "persons": [],
      "organizations": [],
      "locations": [
        {
          "name": "Andalusia Il bil",
          "sentiment": "none"
        },
        {
          "name": "Valencia",
          "sentiment": "none"
        }
      ]
    },
    "syndication": {
      "syndicated": null,
      "syndicate_id": null,
      "first_syndicated": false
    },
    "rating": null,
    "crawled": "2024-11-01T10:37:18.049+02:00",
    "updated": "2024-11-01T10:37:18.049+02:00"
  },
  {
    "uuid": "112a500fd07dbcd12995aa7adbd72cec8fe48940",
    "url": "https://www.thehindu.com/news/cities/Delhi/aap-hails-victory-of-truth-after-sc-grants-interim-bail-to-arvind-kejriwal/article68396003.ece",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "PTI",
    "published": "2024-07-12T00:00:00Z",
    "title": "AAP hails ‘victory of truth’ after SC grants interim bail to Arvind Kejriwal - The Hindu",
    "text": "The AAP on July 12 hailed the Supreme Court for granting interim bail to Delhi Chief Minister Arvind Kejriwal in the excise policy scam case filed by the ED and said this has \"exposed\" the BJP \"conspiracy\" against him.\nMr. Kejriwal, who is the national convenor of the AAP, however, will remain in jail as the Central Bureau of Investigation (CBI) had arrested him in a corruption case related to the alleged scam while he was in custody of the Enforcement Directorate (ED).\nAlso Read: Why has CBI arrested Arvind Kejriwal and what happens next? | Explained\nIn a joint press conference, Aam Aadmi Party (AAP) leaders Atishi, Saurabh Bharadwaj and Sandeep Pathak termed the Supreme Court verdict as a \"victory of truth\".\nEarlier, the party in a post on X said \"Satyamev jayate (truth alone triumphs)\".\nThe BJP knew that Mr. Kejriwal would get bail from the Supreme Court in the ED's money laundering case linked to the excise policy matter and it, therefore, got him arrested by the CBI, Atishi claimed.\nMr. Kejriwal was honest, is honest and will remain honest, she said and added that every court of law has exposed the BJP's \"conspiracy\" against him.\nRajya Sabha member Pathak termed the court order \"historic\" and alleged that the excise policy case was a \"circus\" by the BJP.\nThe AAP is hopeful that Mr. Kejriwal will also be granted bail in the excise policy case filed by the CBI, Mr. Bharadwaj said.\nWhile granting the interim bail, the apex court said Mr. Kejriwal has suffered incarceration for over 90 days.\nRead Comments Copy link Email Facebook Twitter Telegram LinkedIn WhatsApp Reddit READ LATER Remove SEE ALL PRINT",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "positive",
    "categories": [
      "Human Interest",
      "Crime, Law and Justice",
      "Politics"
    ],
    "ai_allow": false,
    "webz_reporter": false,
    "external_links": [],
    "external_images": [],
    "entities": {
      "persons": [
        {
          "name": "arvind",
          "sentiment": "negative"
        },
        {
          "name": "arvind kejriwal",
          "sentiment": "negative"
        },
        {
          "name": "atishi",
          "sentiment": "none"
        },
        {
          "name": "saurabh bharadwaj",
          "sentiment": "none"
        },
        {
          "name": "kejriwal",
          "sentiment": "none"
        },
        {
          "name": "sandeep pathak",
          "sentiment": "none"
        }
      ],
      "organizations": [
        {
          "name": "supreme court",
          "sentiment": "negative"
        },
        {
          "name": "atishi",
          "sentiment": "none"
        },
        {
          "name": "central bureau of investigation (cbi",
          "sentiment": "none"
        },
        {
          "name": "bjp",
          "sentiment": "none"
        },
        {
          "name": "cbi",
          "sentiment": "none"
        },
        {
          "name": "aam aadmi party",
          "sentiment": "none"
        },
        {
          "name": "enforcement directorate",
          "sentiment": "none"
        }
      ],
      "locations": [
        {
          "name": "delhi",
          "sentiment": "none"
        }
      ]
    },
    "rating": null,
    "crawled": "2024-07-12T11:04:15.893+03:00",
    "updated": "2024-07-19T21:50:10.957+03:00"
  },
  {
    "uuid": "74cfa813e81b28a6f3ebf303836ad3fd6bd00df7",
    "url": "https://news.china.com/socialgd/10000169/20250328/48142538.html",
    "ord_in_thread": 0,
    "author": "#5434",
    "published": "2025-03-28T00:00:00Z",
    "title": "佛山一公司被曝\"变相强制加班\" 公司回应加班10晚可帮缴社保个人部分_新闻频道_中华网",
    "text": "近日，广东佛山一家企业的内部通知在网络上引发热议。据网友爆料，佛山汇创塑料模具有限公司下发通知，要求员工每月加班不少于10晚，否则需自行承担原本由公司代缴的个人部分社保费用。此事迅速在社交平台上引起关注，不少网友质疑企业是否在“变相强制加班”。\n事情发生在3月26日，根据网上流传的截图显示，该公司明确表示：“每个月加班天数达不到10晚的员工，个人应缴的社保部分公司将不再代缴，由员工自行承担。”有员工表示，公司此举让人感觉是在用缴社保的权利诱导员工自愿加班，虽然表面上说是“鼓励”，实际上却像是“软性强制”。\n3月27日，面对舆论质疑，汇创塑料模具有限公司作出回应。公司方面表示，该规定并非强制加班，员工有权选择是否参与加班。企业代表称：“我们没有强制大家一定要加班，如果你愿意加班，公司不仅会支付相应的加班费，还会给予提成奖励，并且会代缴你应负担的社保个人部分。”而如果员工选择不加班，那么每月个人应缴纳的社保部分——大约四百多元——就需要由员工自己承担。\n据悉，企业为员工缴纳社保分为公司承担部分和员工个人承担部分。通常情况下，这两部分都是由公司统一代缴后从工资中扣除。但该公司此次做法引发质疑的关键在于，将是否加班与个人社保缴纳挂钩，是否涉嫌违法尚需进一步判断。有法律人士指出，如果公司以“自愿”为幌子，通过经济手段“引导”员工超时工作，可能涉嫌违反《劳动法》有关工作时间和强制劳动的规定。",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "chinese",
    "sentiment": "negative",
    "categories": [
      "Labor",
      "Crime, Law and Justice",
      "Social Issue"
    ],
    "topics": [
      "Labor->employee",
      "Labor->labour relations",
      "Labor->wages and benefits",
      "Crime, Law and Justice->corporate crime",
      "Crime, Law and Justice->administrative law",
      "Social Issue->discrimination",
      "Social Issue->social problem",
      "Social Issue->abusive behaviour"
    ],
    "ai_allow": true,
    "has_canonical": false,
    "breaking": false,
    "webz_reporter": false,
    "external_links": [],
    "entities": {
      "persons": [],
      "locations": [],
      "organizations": []
    },
    "syndication": {
      "syndicated": null,
      "syndicate_id": null,
      "first_syndicated": false
    },
    "trust": {
      "categories": []
    },
    "rating": null,
    "crawled": "2025-03-28T10:23:31.723+03:00",
    "updated": "2025-03-28T10:23:31.723+03:00"
  }
]